Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | EPOR | P19235 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26009028 | 1.00 | KMT2A (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| SCHEMBL30350460 | 1.00 | KMT2A (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| SCHEMBL31714158 | 1.00 | KMT2A (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| Hydrochloric Acid SCHEMBL25357186 | 0.99 | TLR2 (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| Hydrochloric Acid SCHEMBL25359281 | 0.99 | TLR2 (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| Hydrochloric Acid SCHEMBL25357179 | 0.99 | TLR2 (0.43) | KMT2ATLR2FABP5FABP7EPOR | |
| SCHEMBL27887204 | 0.97 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7CASP3 | |
| SCHEMBL30927075 | 0.97 | KMT2A (0.44) | KMT2ATLR2FABP5FABP7CASP3 | |
| SCHEMBL25182297 | 0.90 | TLR2 (0.43) | KMT2ATLR2FABP5FABP7FOLH1 | |
| SCHEMBL30792938 | 0.90 | TLR2 (0.43) | KMT2ATLR2FABP5FABP7FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224598-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250332264-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| US-12415834-B2 | GhR-binding peptide and composition comprising same | PEPTIDREAM INC. (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | JANSSEN BIOTECH INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4355760-A1 | GHR-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PeptiDream Inc. (JP) | 2024-04-24 | — | — | EP | disclosed |
| CN-117677628-A | GHR binding pending peptides and compositions comprising the same | 肽梦想株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230012823-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2022265109-A1 | GHR-BINDING PENDING PEPTIDE AND COMPOSITION COMPRISING SAME | PEPTIDREAM INC. (JP) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415834-B2 | GhR-binding peptide and composition comprising same | GHRHR, GHSR, GIPR | KMT2A 4296/4885TLR2 2767/4885FABP5 296/4885 |
| US-20230012823-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | GHRHR, GHSR, GIPR | KMT2A 4296/4885TLR2 2767/4885FABP5 296/4885 |
| US-20250332264-A1 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | GHRHR, GHSR, GIPR | KMT2A 4296/4885TLR2 2767/4885FABP5 296/4885 |
| US-20240352073-A1 | BICYCLIC PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL17A | KMT2A 3912/4885TLR2 269/4885FABP5 2708/4885 |
| US-20240409598-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL36G | KMT2A 3676/4885TLR2 641/4885FABP5 3799/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 3524/4885TLR2 268/4885FABP5 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.